{"transactions":[{"id":683966,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-08-18T21:00:14.000Z","date":"2026-08-17","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":4.91,"value":24550.0,"ownership":{"direct":true},"balance_after":207593,"source":{"system":"sec-edgar","filing":"0002043558-26-000005","document":"form4-08182026_050802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000204355826000005/form4-08182026_050802.xml","form_type":"4"}},{"id":683965,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-08-18T21:00:14.000Z","date":"2026-08-14","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":5.06,"value":101200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.04 to $5.088 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":202593,"source":{"system":"sec-edgar","filing":"0002043558-26-000005","document":"form4-08182026_050802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000204355826000005/form4-08182026_050802.xml","form_type":"4"}},{"id":744999,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-09T20:15:14.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":512269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by a committee of the Issuer's board of directors on December 23, 2025, subject to shareholder approval of an amendment to the Issuer's 2018 Equity Incentive Plan under which the option was granted. The Issuer's shareholders approved the amendment on June 5, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $15.00, and 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $25.00, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":512269,"derivative":{"exercise_price":8.21,"expiration_date":"2035-12-23","underlying":"Common Stock","underlying_shares":512269},"source":{"system":"sec-edgar","filing":"0002043558-26-000002","document":"form4-06092026_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000204355826000002/form4-06092026_040610.xml","form_type":"4"}},{"id":988960,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Series C Warrant (right to buy)","published_at":"2025-11-26T00:00:11.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":23577,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities are included within 94,311 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":23577,"derivative":{"exercise_price":6.315,"expiration_date":"2030-11-25","underlying":"Common Stock","underlying_shares":23577},"source":{"system":"sec-edgar","filing":"0002043558-25-000003","document":"form4-11252025_071107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000204355825000003/form4-11252025_071107.xml","form_type":"4"}},{"id":988959,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-11-26T00:00:11.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":94311,"price":4.2425,"value":400114.4175,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split."}],"balance_after":182593,"source":{"system":"sec-edgar","filing":"0002043558-25-000003","document":"form4-11252025_071107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000204355825000003/form4-11252025_071107.xml","form_type":"4"}},{"id":1200777,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-18T22:45:07.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/8th of the total shares subject to the option shall vest on September 14, 2025, and 1/48th of the total shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":850000,"derivative":{"exercise_price":0.89,"expiration_date":"2035-03-14","underlying":"Common Stock","underlying_shares":850000},"source":{"system":"sec-edgar","filing":"0001415889-25-008506","document":"form4-03182025_060303.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000141588925008506/form4-03182025_060303.xml","form_type":"4"}},{"id":1351277,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Series B Warrants (right to buy)","published_at":"2024-11-26T21:15:13.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":140449,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."}],"balance_after":140449,"derivative":{"exercise_price":1.335,"exercise_date":"2024-11-22","expiration_date":"2029-11-22","underlying":"Common Stock","underlying_shares":140449},"source":{"system":"sec-edgar","filing":"0001415889-24-027711","document":"form4-11262024_041106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000141588924027711/form4-11262024_041106.xml","form_type":"4"}},{"id":1351276,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Series A Warrants (right to buy)","published_at":"2024-11-26T21:15:13.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":140449,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."}],"balance_after":140449,"derivative":{"exercise_price":1.068,"exercise_date":"2024-11-22","expiration_date":"2025-11-22","underlying":"Common Stock","underlying_shares":140449},"source":{"system":"sec-edgar","filing":"0001415889-24-027711","document":"form4-11262024_041106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000141588924027711/form4-11262024_041106.xml","form_type":"4"}},{"id":1351275,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-11-26T21:15:13.000Z","date":"2024-11-26","kind":"gift","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":882826,"source":{"system":"sec-edgar","filing":"0001415889-24-027711","document":"form4-11262024_041106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000141588924027711/form4-11262024_041106.xml","form_type":"4"}},{"id":1351274,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-11-26T21:15:13.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":280898,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."}],"balance_after":832826,"source":{"system":"sec-edgar","filing":"0001415889-24-027711","document":"form4-11262024_041106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000141588924027711/form4-11262024_041106.xml","form_type":"4"}},{"id":1374404,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-11-07T02:02:43.000Z","date":"2024-11-06","kind":"grant","planned":false,"acquired":true,"shares":2000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/8th of the total shares subject to the option shall vest on May 5, 2025, and 1/48th of the total shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":2000000,"derivative":{"exercise_price":0.7463,"expiration_date":"2034-11-06","underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0001415889-24-026286","document":"form4-11072024_021140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000141588924026286/form4-11072024_021140.xml","form_type":"4"}}]}